FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory, and metabolic disorders, today announced that it entered into agreement with Applied Science and Performance Institute (ASPI) in Tampa, Florida, on April 24, 2024 to conduct "A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Safety and Efficacy of unbuzzd in Healthy Volunteers in an Induced State of Alcohol Intoxication (METAL-2 TRIAL)".

unbuzzd is a unique dietary supplement with natural ingredients, vitamins and GRAS (Generally Recognized as Safe) ingredients that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism, and may accelerate alcohol metabolism in the body. In the METAL-2 trial, the ability of unbuzzd to reverse the effects of acute alcohol intoxication will be compared to a placebo in a crossover design with thirty healthy volunteers randomized in the trial. FSD Pharma licensed this technology to Celly Nutrition Corp. for the recreational sale of unbuzzd.

"We are thrilled to be working with ASPI's agile and experienced team to conduct this study given their expertise in clinical trials with dietary supplements in the health and wellness industry. This trial marks a key milestone and we believe is important in establishing our company as a leader in products targeting alcohol intoxication" said Mr. Zeeshan Saeed, CEO and founder of FSD Pharma.